EXTI - only public co. developing liver device

To: CENTrader who wrote (788)	2/16/2000 7:40:00 PM
From: MaxLeverage	of 1063

Not new , but noteworthy from Exten's site. "The company expects to 1) directly sell devices to hospitals, particularly those with liver transplant programs and 2) set up freestanding outpatient treatment centers much like renal dialysis centers, so that patients can resist or overcome liver disease or poisoning by periodic or short-term treatments. 3) Sell international licensing agreements. The potential market for artificial liver support is projected to be hundreds of millions of dollars annually in the US alone. We intend to offer the most cost-effective and biologically efficient treatment to capture the majority of that market." Now, let's see..door number two looks interesting! exten.com

Share	Recommend \| Keep \| Reply \| Mark as Last Read

To: Shawn Donahue who wrote (782)	2/16/2000 11:14:00 PM
From: Shawn Donahue	of 1063

To ALL EXTI investors, Here is feedback from the Biomedical Conference(see post #782)that EXTI attended...It looks like it may prove fruitful! IMO :) Shawn Subj: Biomed conference on Saturday Date: 00-02-14 19:53:59 EST From: EXTIXENO To: STDSAD Dear Shawn, Jerry Newmin and I did end up going to part of the Biomed conference on Saturday. It was basically a series of company presentations to/for individual investors, but the lunch keynote speaker, Burrill, gave one very good overview of the changes in the biosciences business environment. He and maybe 3 other people there were ptentially good contacts and we are, have been or will be in touch with them. Thanks again for encouraging us to go. Barbara L. Corbett

Share	Recommend \| Keep \| Reply \| Mark as Last Read

To: YadaBoy who wrote (791)	2/18/2000 3:50:00 PM
From: Robert Jones	of 1063

Pretty hard not to notice this kind of a move. I have owned this stock some years, but have only a minimal acquaintance with their technology. With that qualifier, here's what I've learning from performing my due diligence. We have a biotech with a device that's beyond the talking stage. There is evidently a urgent medical need for what this device does. We will be submitting to the FDA for level 1 trials this year. Financing (at least partially) is supposedly in place. In sum, EXTI appears to be a better position than many other biotech startups I've seen, some of which sell for several dollars per share. Thus, I'm not surprised that people perceive EXTI as a attractive speculation at its recent price levels. Ergo, a runup like we're seeing today. Next week should be interesting!

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (1)

To: PROLIFE who wrote (793)	2/22/2000 5:26:00 PM
From: Shawn Donahue	of 1063

Dan, FDA approval is of course for clinical applications, but EXTI is also developing the SybiolR for Pharmaceutical companes to use as a safe (better than using humans as guinea pigs, imo), and inexpensive way to test new drugs and this would not require FDA approval... Message 12667583 Pre-clinical and clinical trials will be directed toward FDA approval for clinical applications in the US. Sybiol© could also provide pharmaceutical companies with a safe, inexpensive way to test new drugs, an application which may not require FDA approval. Below is also a post from another EXTI investor that sees the potential for SybiolR, even before FDA approval: Message 12579163 "if we can just demonstrate a device that works in Phase I trials or Phase I & II, I think we would discover that large companies with deep pockets would then become very interested in either acquiring our company or, at least,acquiring our intellectual property rights" I hope that this helps, Shawn

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (1)